| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10918545 | Radiotherapy and Oncology | 2014 | 6 Pages |
Abstract
Axitinib radiosensitizes tumor endothelial cells and enhances tumor cure with SDRT, which may permit dose de-escalation and significantly expand the range of clinical indications for SDRT.
Keywords
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Shyam S. Rao, Chris Thompson, Jin Cheng, Adriana Haimovitz-Friedman, Simon N. Powell, Zvi Fuks, Richard N. Kolesnick,